The "Weight Loss/Weight Management (Obesity) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Weight Loss/Weight Management (Obesity) market. A detailed picture of the Weight Loss/Weight Management (Obesity) pipeline landscape is provided, which includes the disease overview and treatment guidelines.

The assessment part of the report embraces in-depth Weight Loss/Weight Management (Obesity) commercial assessment and clinical assessment of the Weight Loss/Weight Management (Obesity) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Weight Loss/Weight Management (Obesity) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Weight Loss/Weight Management (Obesity) .
• In the coming years, the Weight Loss/Weight Management (Obesity) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Weight Loss/Weight Management (Obesity) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Weight Loss/Weight Management (Obesity) treatment market. Several potential therapies for Weight Loss/Weight Management (Obesity) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Weight Loss/Weight Management (Obesity) market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Weight Loss/Weight Management (Obesity) ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
  

Key Topics Covered:

1. Report Introduction

2. Weight Loss/Weight Management (Obesity)

2.1. Overview

2.2. History

2.3. Weight Loss/Weight Management (Obesity) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Weight Loss/Weight Management (Obesity) Diagnosis

2.6.1. Diagnostic Guidelines

3. Weight Loss/Weight Management (Obesity) Current Treatment Patterns

3.1. Weight Loss/Weight Management (Obesity) Treatment Guidelines

4. Weight Loss/Weight Management (Obesity) - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Weight Loss/Weight Management (Obesity) companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Weight Loss/Weight Management (Obesity) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Weight Loss/Weight Management (Obesity) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Weight Loss/Weight Management (Obesity) Late Stage Products (Phase-III)

7. Weight Loss/Weight Management (Obesity) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Weight Loss/Weight Management (Obesity) Discontinued Products

13. Weight Loss/Weight Management (Obesity) Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Weight Loss/Weight Management (Obesity) Key Companies

15. Weight Loss/Weight Management (Obesity) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Weight Loss/Weight Management (Obesity) Unmet Needs

18. Weight Loss/Weight Management (Obesity) Future Perspectives

19. Weight Loss/Weight Management (Obesity) Analyst Review

20. Appendix

21. Report Methodology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gaynvy

View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005396/en/